FXR agonists as therapeutic agents for non-alcoholic fatty liver disease (Q38359118)

2 September 2017

1 reference

title

FXR agonists as therapeutic agents for non-alcoholic fatty liver disease (English)

1 reference

non-alcoholic fatty liver

2 September 2017

1 reference

metabolic dysfunction–associated steatotic liver disease

inferred from title

1 reference

Rotonya M Carr

1

1 reference

PubMed ID

25690590

2 September 2017

Andrea E Reid

series ordinal

2

1 reference

2 September 2017

1 April 2015

1 reference

Current Atherosclerosis Reports

2 September 2017

1 reference

2 September 2017

17

1 reference

2 September 2017

4

1 reference

2 September 2017

500

1 reference

https://scigraph.springernature.com/pub.10.1007/s11883-015-0500-2

2 September 2017

0 references

cites work

Epidemiology of non-alcoholic fatty liver disease.

1 reference

https://api.crossref.org/works/10.1007%2FS11883-015-0500-2

Prevalence of hepatic steatosis in an urban population in the United States: impact of ethnicity

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11883-015-0500-2

Nonalcoholic fatty liver, steatohepatitis, and the metabolic syndrome

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11883-015-0500-2

Independent association between nonalcoholic fatty liver disease and cardiovascular disease in the US population

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11883-015-0500-2

NAFLD as a risk factor for the development of diabetes and the metabolic syndrome: an eleven-year follow-up study

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11883-015-0500-2

Long-term follow-up of patients with nonalcoholic fatty liver

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11883-015-0500-2

Frequency and outcomes of liver transplantation for nonalcoholic steatohepatitis in the United States.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11883-015-0500-2

The diagnosis and management of non-alcoholic fatty liver disease: practice Guideline by the American Association for the Study of Liver Diseases, American College of Gastroenterology, and the American Gastroenterological Association

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11883-015-0500-2

Design and validation of a histological scoring system for nonalcoholic fatty liver disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11883-015-0500-2

Randomized controlled trial testing the effects of weight loss on nonalcoholic steatohepatitis

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11883-015-0500-2

Comparison of strategies for sustaining weight loss: the weight loss maintenance randomized controlled trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11883-015-0500-2

Fatty liver: a novel component of the metabolic syndrome

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11883-015-0500-2

Orlistat for overweight subjects with nonalcoholic steatohepatitis: A randomized, prospective trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11883-015-0500-2

Evolution of inflammation in nonalcoholic fatty liver disease: the multiple parallel hits hypothesis

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11883-015-0500-2

Role of AMP-activated protein kinase in mechanism of metformin action

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11883-015-0500-2

Systematic review: the epidemiology and natural history of non-alcoholic fatty liver disease and non-alcoholic steatohepatitis in adults

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11883-015-0500-2

A placebo-controlled trial of pioglitazone in subjects with nonalcoholic steatohepatitis

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11883-015-0500-2

Randomized, placebo-controlled trial of pioglitazone in nondiabetic subjects with nonalcoholic steatohepatitis

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11883-015-0500-2

Pioglitazone, vitamin E, or placebo for nonalcoholic steatohepatitis

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11883-015-0500-2

Vitamin E and cardiovascular disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11883-015-0500-2

Effect of selenium and vitamin E on risk of prostate cancer and other cancers: the Selenium and Vitamin E Cancer Prevention Trial (SELECT)

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11883-015-0500-2

Role of bile acids and bile acid receptors in metabolic regulation

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11883-015-0500-2

Anti-inflammatory and metabolic actions of FXR: insights into molecular mechanisms.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11883-015-0500-2

Identification of a nuclear receptor for bile acids

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11883-015-0500-2

Bile acids: natural ligands for an orphan nuclear receptor

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11883-015-0500-2

Endogenous bile acids are ligands for the nuclear receptor FXR/BAR

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11883-015-0500-2

A G protein-coupled receptor responsive to bile acids

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11883-015-0500-2

Lipid metabolism and liver inflammation. II. Fatty liver disease and fatty acid oxidation

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11883-015-0500-2

Bile salt biotransformations by human intestinal bacteria

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11883-015-0500-2

The hepatic response to FGF19 is impaired in patients with nonalcoholic fatty liver disease and insulin resistance.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11883-015-0500-2

Nutritional regulation of bile acid metabolism is associated with improved pathological characteristics of the metabolic syndrome

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11883-015-0500-2

Serum bile acids are higher in humans with prior gastric bypass: potential contribution to improved glucose and lipid metabolism

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11883-015-0500-2

Effects of diabetes mellitus on cholesterol metabolism in man.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11883-015-0500-2

Metabolism of cholesterol and plasma triglycerides in nonketotic diabetes mellitus.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11883-015-0500-2

Improved glycemic control with colesevelam treatment in patients with type 2 diabetes is not directly associated with changes in bile acid metabolism

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11883-015-0500-2

Monitoring bile acid transport in single living cells using a genetically encoded Förster resonance energy transfer sensor.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11883-015-0500-2

Bile acid-mediated control of liver triglycerides.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11883-015-0500-2

Natural structural variants of the nuclear receptor farnesoid X receptor affect transcriptional activation

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11883-015-0500-2

Generation of multiple farnesoid-X-receptor isoforms through the use of alternative promoters

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11883-015-0500-2

Targeted disruption of the nuclear receptor FXR/BAR impairs bile acid and lipid homeostasis.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11883-015-0500-2

Farnesoid X receptor is essential for normal glucose homeostasis

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11883-015-0500-2

Glucose regulates the expression of the farnesoid X receptor in liver

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11883-015-0500-2

Genetic variation in NR1H4 encoding the bile acid receptor FXR determines fasting glucose and free fatty acid levels in humans

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11883-015-0500-2

Contribution of de novo fatty acid synthesis to hepatic steatosis and insulin resistance: lessons from genetically engineered mice

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11883-015-0500-2

Bile acids lower triglyceride levels via a pathway involving FXR, SHP, and SREBP-1c

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11883-015-0500-2

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11883-015-0500-2

Bile acids induce the expression of the human peroxisome proliferator-activated receptor alpha gene via activation of the farnesoid X receptor

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11883-015-0500-2

Regulation of carbohydrate metabolism by the farnesoid X receptor

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11883-015-0500-2

What is the metabolic role of phosphoenolpyruvate carboxykinase?

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11883-015-0500-2

Coordinated control of cholesterol catabolism to bile acids and of gluconeogenesis via a novel mechanism of transcription regulation linked to the fasted-to-fed cycle

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11883-015-0500-2

Bile acids regulate gluconeogenic gene expression via small heterodimer partner-mediated repression of hepatocyte nuclear factor 4 and Foxo1.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11883-015-0500-2

A regulatory cascade of the nuclear receptors FXR, SHP-1, and LRH-1 represses bile acid biosynthesis

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11883-015-0500-2

The role of the gut microbiota in nonalcoholic fatty liver disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11883-015-0500-2

Nuclear factor-kappaB and the hepatic inflammation-fibrosis-cancer axis

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11883-015-0500-2

Farnesoid X receptor antagonizes nuclear factor kappaB in hepatic inflammatory response

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11883-015-0500-2

Spontaneous hepatocarcinogenesis in farnesoid X receptor-null mice

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11883-015-0500-2

Spontaneous development of liver tumors in the absence of the bile acid receptor farnesoid X receptor

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11883-015-0500-2

Yin Yang 1 promotes hepatic steatosis through repression of farnesoid X receptor in obese mice.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11883-015-0500-2

Hepatic steatosis exacerbated by endoplasmic reticulum stress-mediated downregulation of FXR in aging mice.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11883-015-0500-2

Activation of farnesoid X receptor (FXR) protects against fructose-induced liver steatosis via inflammatory inhibition and ADRP reduction.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11883-015-0500-2

Farnesoid X receptor agonist WAY-362450 attenuates liver inflammation and fibrosis in murine model of non-alcoholic steatohepatitis.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11883-015-0500-2

The nuclear receptor SHP mediates inhibition of hepatic stellate cells by FXR and protects against liver fibrosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11883-015-0500-2

Significance and mechanism of CYP7a1 gene regulation during the acute phase of liver regeneration

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11883-015-0500-2

FXR regulates liver repair after CCl4-induced toxic injury

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11883-015-0500-2

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11883-015-0500-2

Development of insulin resistance and hyperphagia in Zucker fatty rats

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11883-015-0500-2

FXR activation reverses insulin resistance and lipid abnormalities and protects against liver steatosis in Zucker (fa/fa) obese rats

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11883-015-0500-2

Absence of perilipin 2 prevents hepatic steatosis, glucose intolerance and ceramide accumulation in alcohol-fed mice

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11883-015-0500-2

Protection against fatty liver but normal adipogenesis in mice lacking adipose differentiation-related protein

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11883-015-0500-2

Inhibition of ADRP prevents diet-induced insulin resistance

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11883-015-0500-2

Ageing Fxr deficient mice develop increased energy expenditure, improved glucose control and liver damage resembling NASH

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11883-015-0500-2

Mouse models in non-alcoholic fatty liver disease and steatohepatitis research.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11883-015-0500-2

Disruption of phospholipid and bile acid homeostasis in mice with nonalcoholic steatohepatitis.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11883-015-0500-2

Farnesoid X receptor activation improves erectile function in animal models of metabolic syndrome and diabetes

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11883-015-0500-2

Antiatherosclerotic effect of farnesoid X receptor

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11883-015-0500-2

The incidence and risk factors of hepatocellular carcinoma in patients with nonalcoholic steatohepatitis

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11883-015-0500-2

FXR controls the tumor suppressor NDRG2 and FXR agonists reduce liver tumor growth and metastasis in an orthotopic mouse xenograft model

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11883-015-0500-2

Regulation of ileal bile acid-binding protein expression in Caco-2 cells by ursodeoxycholic acid: role of the farnesoid X receptor

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11883-015-0500-2

Bile acids: regulation of apoptosis by ursodeoxycholic acid

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11883-015-0500-2

Ursodeoxycholic acid for treatment of nonalcoholic steatohepatitis: results of a randomized trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11883-015-0500-2

Bile acid derivatives as ligands of the farnesoid X receptor. Synthesis, evaluation, and structure-activity relationship of a series of body and side chain modified analogues of chenodeoxycholic acid

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11883-015-0500-2

Efficacy and safety of the farnesoid X receptor agonist obeticholic acid in patients with type 2 diabetes and nonalcoholic fatty liver disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11883-015-0500-2

Nonalcoholic fatty liver disease: a feature of the metabolic syndrome

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11883-015-0500-2

Cytokeratin-18 fragment levels as noninvasive biomarkers for nonalcoholic steatohepatitis: a multicenter validation study

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11883-015-0500-2

The farnesoid X receptor -1G>T polymorphism influences the lipid response to rosuvastatin

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11883-015-0500-2

The TGR5 receptor mediates bile acid-induced itch and analgesia

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11883-015-0500-2

Temporal effects of ethanol consumption on energy homeostasis, hepatic steatosis, and insulin sensitivity in mice

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11883-015-0500-2

The FXR agonist 6ECDCA reduces hepatic steatosis and oxidative stress induced by ethanol and low-protein diet in mice

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11883-015-0500-2

MELD accurately predicts mortality in patients with alcoholic hepatitis

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11883-015-0500-2

The farnesoid X-receptor is an essential regulator of cholesterol homeostasis

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11883-015-0500-2

Bile acids reduce endocytosis of high-density lipoprotein (HDL) in HepG2 cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11883-015-0500-2

Activation of farnesoid X receptor attenuates hepatic injury in a murine model of alcoholic liver disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11883-015-0500-2

Role of mesenchymal cell populations in porcine serum-induced rat liver fibrosis

21 January 2018

1 reference

12 December 2020

Synthetic farnesoid X receptor agonists induce high-density lipoprotein-mediated transhepatic cholesterol efflux in mice and monkeys and prevent atherosclerosis in cholesteryl ester transfer protein transgenic low-density lipoprotein receptor (-/-)

1 reference

12 December 2020

Farnesoid X receptor alleviates age-related proliferation defects in regenerating mouse livers by activating forkhead box m1b transcription

1 reference

12 December 2020

Peroxisome Proliferator-Activated Receptor α Protects against Obesity-Induced Hepatic Inflammation

1 reference

12 December 2020

Is Cirrhosis of the Liver Experimentally Produced by CC14 an Adequate Model of Human Cirrhosis?

1 reference

12 December 2020

Waist circumference and not body mass index explains obesity-related health risk

1 reference

12 December 2020

Transport of bile acids in hepatic and non-hepatic tissues.

1 reference

12 December 2020

Vitamin E and vitamin C treatment improves fibrosis in patients with nonalcoholic steatohepatitis

1 reference

12 December 2020

Prolonged bile duct obstruction: a new experimental model for cirrhosis in the rat

1 reference

12 December 2020

Farnesoid X nuclear receptor ligand obeticholic acid for non-cirrhotic, non-alcoholic steatohepatitis (FLINT): a multicentre, randomised, placebo-controlled trial

1 reference

12 December 2020

Nuclear receptor-dependent bile acid signaling is required for normal liver regeneration

1 reference

12 December 2020

A randomized controlled trial of high-dose ursodesoxycholic acid for nonalcoholic steatohepatitis

1 reference

12 December 2020

Cholate inhibits high-fat diet-induced hyperglycemia and obesity with acyl-CoA synthetase mRNA decrease

1 reference

12 December 2020

10.1007/S11883-015-0500-2

Identifiers

DOI

1 reference

PubMed ID

25690590

Dimensions Publication ID

2 September 2017

0 references

1 reference

PubMed ID

25690590